Drugs / FKS518
last change Aug 2023 re-read 2 minutes ago

FKS518

Developed for
postmenopausal osteoporosis
Investigated by
Fresenius Kabi SwissBioSim GmbH

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04934072 Jun 2021 → Aug 2023 postmenopausal osteoporosis Fresenius Kabi SwissBioSim GmbH Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as FKS518 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04934072
Route Subcutaneous subcutaneously by single-use prefilled syringe (PFS)” NCT04934072